NEWS RELATED TO BIOBIDE
The results of BIOBIDE´s participation in the European FP7 project (ZF-Cancer) have been published in Oncoge.
Monday, 16 January 2012 13:30
The zebrafish has emerged as a new important system for cancer research because the zebrafish genome contains all orthologs of human oncogenes and forms tumors with similar histopathological and gene profiling features as human tumors. The zebrafish provides an in vivo vertebrate model for identifying novel mechanisms of cancer progression and for development of new anticancer compounds in a time- and cost-effective manner.
Based on that, the ZF-CANCER project aimed to develop high-throughput bioassays for target discovery and rapid drug screenings applicable in preclinical validation pipelines.
The results obtained by Biobide in collaboration with the Center for Regenerative Medicine in Barcelona, the Biotech Galapagos and the Salk Institute for Biological Studies (USA), have been published (December 2011) in the prestigious journal ONCOGENE.
In the study, inhibitors of kinases that cause marked inhibition of angiogenesis in zebrafish whole organisms have been identified. Furthermore, the kinase target has been determined, offering an important advancement on many previous screens in which the compound targets are not elucidated, and identify a previously undiscovered role of PhKG1 in angiogenesis. The results provide the first evidence of the PhK holoenzyme having a role in tumorigenesis, offer further insight into the process of angiogenesis and establish PhKG1
In this study, the results highlight the advances in technology that make high-throughput screening a valuable source of compound discovery and emphasize the value of zebrafish as a model organism that lends itself to high-throughput screening techniques, whilst providing very relevant screening parameters due to the whole-organism setting.
http://www.nature.com/onc/journal/vaop/ncurrent/full/onc2011594a.html
Meet BIOBIDE at OUTSOURCING PRECLINICAL DEVELOPMENT in Zurich. November 30-December 1 2011
Monday, 21 November 2011 13:36
BIOBIDE would enjoy to meet you at OUTSOURCING PRECLINICAL DEVELOPMENT in Zurich. November 30-December 1 2011
To schedule a meeting contact: Isabel Hervias (
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
) or
Arantza Muriana ( This e-mail address is being protected from spambots. You need JavaScript enabled to view it )
Zebrafish used as research model to test drug efficacy against cancer
Wednesday, 02 November 2011 13:24
Zebrafish used as research model to test drug efficacy against cancer
The biotechnology company BIOBIDE, has developed a method using the zebrafish animal model to measure the pharmacological efficacy of new moleculesin the research stage for treating cancer. This new assay in which two important pharmaceutical companies have already expressed interest, strengthens Biobide’s support for the zebrafish. The growing number of applications for the zebrafish in the Drug Discovery and Development process has increased the demand for this type of services. This is a trend that is expected to continue in the future.
Specifically, Biobide has developed an assay that makes possible to detect a compound’s capacity to inhibit angiogenesis (the formation of new blood vessels from those already existing). This physiological process is fundamental for tumor growth in metastasis. This process is involved in other pathologies, such as diabetic retinopathy and psoriasis, among others; this is why it is important to have a method to validate compounds that might affect it.
This anti-angiogenesis assay, which is totally automated on Biobide’s High Throughput Screening platform and already available to their clients, was validated using more than 230 compounds with very satisfactory results. It should be pointed out that this assay is the result of Biobide’s participation in the Seventh European Community Framework Program, which promotes the use of animal models in Drug Discovery processes.
New lines of research in Oncology
As a result of the advances made in their research, Biobide was invited to participate in the “European Cancer Cluster Partnering” (ECCP), an European event dedicated to oncology held in the city of Toulouse. There, Scientific Director Carles Callol Massot presented the work and advances made by Biobide in the area of oncology.
Callol also discussed the possibilities presented by the use of zebrafish embryos in the validation of new therapeutic targets in the development of new drugs to fight cancer.
The zebra fish stands out for having a genetic homology of 85% with humans, and the fact that its embryos are transparent and develop in 24-48 hours. These characteristics enable us to study the effects of new compounds administered to these animals at a lower cost and considerably faster than with the other animal models available.
Biobide considered their participation in the “European Cancer Cluster Partnering” to be a very positive experience, as they were able to meet with and present their research lines to biotechnology and pharmaceutical companies from the United States and Europe. These companies have already expressed interest in the company’s work in the area of oncology and the role of the zebrafish applied to Drug Discovery and Development.
http://www.farmanews.com/notas_de_prensa/N3461.html
Normal 0 false false false ES X-NONE X-NONE
Prediction of hepatotoxicity in zebrafish
Friday, 07 October 2011 07:55
Prediction of hepatotoxicity in zebrafish
Journal of Pharmacological and Toxicological Methods
Volume 64, Issue 1, July-August 2011, Page e13
Eighth Annual Focused Issue on ...
ScienceDirect sciencedirect.com
Biobide S.L., San Sebastian, Basque Country, Spain CiC bioGUNE, San Sebastian, Basque Country...............................
Meet BIOBIDE at the Bio-Europe 2011
Friday, 07 October 2011 07:51
Meet BIOBIDE at the Bio-Europe 2011 in Dusseldorf (31 October-2 November)
To schedule a meeting contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
More Articles...
- Biobie at GLOBAL ALZHEIMER´S RESEARCH SUMMIT
- Biobide will exhibit at Miptec 2011. Visit us at booth #D19
- BIOBIDE has been selected to present in the “European Cancer Cluster partnering”
- BIOBIDE is going to participate in the “World Drug Targets Summit” that will be celebrated in Cambridge, Massachusetts from July 20th to 21st
Page 1 of 6